Enrico Franceschi

List of Publications by Citations

148 papers	5,553 citations	34 h-index	72 g-index
181 ext. papers	6,540 ext. citations	4.5 avg, IF	5.19 L-index

#	Paper	IF	Citations
148	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. *Journal of Clinical Oncology*, **2008**, 26, 2192-7	2.2	641
147	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. *New England Journal of Medicine*, **2017**, 376, 1027-1037	59.2	525
146	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncology, The*, **2015**, 16, e534-e542	21.7	425
145	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. *Journal of Clinical Oncology*, **2009**, 27, 1275-9	2.2	249
144	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). *British Journal of Cancer*, **2006**, 95, 1155-60	8.7	193
143	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. *Neuro-Oncology*, **2008**, 10, 361-7	1	188
142	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. *Cancer*, **2005**, 103, 2344-8	6.4	188
141	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. *Cancer*, **2009**, 115, 3512-8	6.4	179
140	Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. *Journal of Clinical Oncology*, **2006**, 24, 4746-53	2.2	156
139	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *British Journal of Cancer*, **2007**, 96, 1047-51	8.7	156
138	Glioblastoma in adults. *Critical Reviews in Oncology/Hematology*, **2008**, 67, 139-52	7	126
137	Temozolomide as salvage treatment in primary brain lymphomas. *British Journal of Cancer*, **2007**, 96, 864-7	8.7	118
136	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. *Clinical Cancer Research*, **2008**, 14, 957-60	12.9	110
135	O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. *Neuro-Oncology*, **2010**, 12, 283-8	1	99
134	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. *European Journal of Cancer*, **2004**, 40, 1682-8	7.5	99
133	Long-term results of a prospective study on the treatment of medulloblastoma in adults. *Cancer*, **2007**, 110, 2035-41	6.4	98
132	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 769-75	3.5	75

131	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. *Journal of Neuro-Oncology*, **2008**, 89, 179-85	4.8	73
130	Salvage temozolomide for prior temozolomide responders. *Cancer*, **2005**, 104, 2473-6	6.4	69
129	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. *European Journal of Cancer*, **2013**, 49, 3609-15	7.5	64
128	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. *Cancer*, **2005**, 104, 143-8	6.4	64
127	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro-Oncology*, **2020**, 22, 684-693	1	62
126	Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2008**, 453, 599-609	5.1	53
125	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. *Neuro-Oncology*, **2016**, 18, 1304-12	1	53
124	Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. *British Journal of Cancer*, **2004**, 90, 36-40	8.7	52
123	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). *Critical Reviews in Oncology/Hematology*, **2009**, 71, 165-79	7	47
122	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. *Neuro-Oncology*, **2012**, 14, 1503-10	1	45
121	Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. *British Journal of Cancer*, **2004**, 91, 1038-44	8.7	45
120	Role of Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. *Oncologist*, **2017**, 22, 432-437	5.7	43
119	Practical management of bevacizumab-related toxicities in glioblastoma. *Oncologist*, **2015**, 20, 166-75	5.7	42
118	Is protracted low-dose temozolomide feasible in glioma patients?. *Neurology*, **2006**, 66, 427-9	6.5	39
117	Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. *Current Treatment Options in Oncology*, **2016**, 17, 49	5.4	37
116	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. *Critical Reviews in Oncology/Hematology*, **2015**, 94, 348-59	7	35
115	The effect of re-operation on survival in patients with recurrent glioblastoma. *Anticancer Research*, **2015**, 35, 1743-8	2.3	35
114	Nitrosoureas in the Management of Malignant Gliomas. *Current Neurology and Neuroscience Reports*, **2016**, 16, 13	6.6	32

113	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. *Expert Review of Anticancer Therapy*, **2012**, 12, 1429-35	3.5	32
112	Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. *Oncologist*, **2010**, 15, 683-94	5.7	32
111	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. *Lancet Oncology, The*, **2020**, 21, e317-e329	21.7	31
110	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. *Oncotarget*, **2016**, 7, 55169-55180	3.3	31
109	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. *Lancet Oncology, The*, **2019**, 20, e715-e728	21.7	31
108	Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?. *Journal of Neuro-Oncology*, **2016**, 128, 235-40	4.8	30
107	Treatment options for recurrent glioblastoma: pitfalls and future trends. *Expert Review of Anticancer Therapy*, **2009**, 9, 613-9	3.5	29
106	Prognostic factors for anaplastic astrocytomas. *Journal of Neuro-Oncology*, **2007**, 81, 295-303	4.8	29
105	Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis. *Journal of Neuro-Oncology*, **2005**, 73, 261-4	4.8	29
104	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. *Oncologist*, **2019**, 24, 521-528	5.7	28
103	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. *BMC Cancer*, **2010**, 10, 48	4.8	27
102	Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome?. *Critical Reviews in Oncology/Hematology*, **2008**, 68, 212-21	7	27
101	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. *World Neurosurgery*, **2018**, 112, e342-e347	2.1	26
100	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. *Journal of Clinical Oncology*, **2016**, 34, LBA2-LBA2	2.2	24
99	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 115-20	3.5	22
98	Patient outcomes following second surgery for recurrent glioblastoma. *Future Oncology*, **2016**, 12, 1039-44	3.6	21
97	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. *Journal of Neuro-Oncology*, **2016**, 128, 157-162	4.8	21
96	Second surgery for recurrent glioblastoma: advantages and pitfalls. *Expert Review of Anticancer Therapy*, **2013**, 13, 583-7	3.5	20

95	Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. *Magnetic Resonance Imaging*, **2003**, 21, 1003-7	3.3	20
94	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. *CNS Drugs*, **2017**, 31, 675-684	6.7	19
93	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. *Neuro-Oncology Practice*, **2014**, 1, 166-171	2.2	19
92	Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. *European Journal of Cancer*, **2012**, 48, 896-903	7.5	18
91	Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. *Journal of Clinical Pathology*, **2015**, 68, 859-69	3.9	16
90	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. *Journal of Neuro-Oncology*, **2017**, 135, 245-254	4.8	16
89	Medulloblastomas in adults: prognostic factors and lessons from paediatrics. *Current Opinion in Neurology*, **2011**, 24, 626-32	7.1	15
88	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. *Future Oncology*, **2018**, 14, 1559-1567	3.6	15
87	Immunotherapy in head and neck cancer: evidence and perspectives. *Immunotherapy*, **2017**, 9, 1351-1358	3.8	13
86	Shedding light on adult medulloblastoma: current management and opportunities for advances. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, e82-7	7.1	13
85	Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. *Journal of Neuro-Oncology*, **2006**, 79, 299-305	4.8	13
84	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. *Expert Review of Anticancer Therapy*, **2020**, 20, 785-795	3.5	13
83	Defining EGFR amplification status for clinical trial inclusion. *Neuro-Oncology*, **2019**, 21, 1263-1272	1	12
82	Predictive markers of immune response in glioblastoma: hopes and facts. *Future Oncology*, **2020**, 16, 1053-1063	3.6	10
81	Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. *Expert Review of Anticancer Therapy*, **2010**, 10, 179-84	3.5	10
80	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. *Journal of Clinical Oncology*, **2018**, 36, 2023-2023	2.2	10
79	Bevacizumab in recurrent glioblastoma: open issues. *Future Oncology*, **2015**, 11, 2655-2665	3.6	9
78	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. *Journal of Neuro-Oncology*, **2018**, 139, 383-388	4.8	9

77	Resistance to antiangiogenic therapies. *Future Oncology*, **2014**, 10, 1417-25	3.6	9
76	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. *Oncotarget*, **2017**, 8, 55575-55581	3.3	9
75	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. *European Journal of Cancer*, **2020**, 137, 10-17	7.5	9
74	Post progression survival in glioblastoma: where are we?. *Journal of Neuro-Oncology*, **2015**, 121, 399-404	4.8	8
73	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. *Future Oncology*, **2020**, 16, 1433-1439	3.6	8
72	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. *Future Oncology*, **2018**, 14, 1063-1069	3.6	7
71	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. *Future Oncology*, **2013**, 9, 1653-64	3.6	7
70	Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study. *BMC Cancer*, **2020**, 20, 755	4.8	7
69	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. *Oncologist*, **2021**, 26, 865-878	5.7	7
68	The role of systemic and targeted therapies in brain metastases. *Expert Review of Anticancer Therapy*, **2014**, 14, 93-103	3.5	6
67	Primary brain tumors in the elderly population. *Current Treatment Options in Neurology*, **2011**, 13, 427-35	4.4	6
66	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. *Neuro-Oncology Advances*, **2020**, 2, vdz051	0.9	6
65	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. *CNS Oncology*, **2021**, 10, CNS72	4	6
64	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. *Diagnostics*, **2021**, 11,	3.8	6
63	Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1) in brain tumors of a cohort of Italian patients. *Scientific Reports*, **2018**, 8, 4459	4.9	5
62	New agents and new end points for recurrent gliomas. *Journal of Clinical Oncology*, **2011**, 29, e245-6; author reply e247	2.2	5
61	Association between response to primary treatments and MGMT status in glioblastoma. *Expert Review of Anticancer Therapy*, **2008**, 8, 1781-6	3.5	5
60	Neuro-Oncology During the COVID-19 Outbreak: A Hopeful Perspective at the End of the Italian Crisis. *Frontiers in Medicine*, **2020**, 7, 594610	4.9	5

59	Glioblastoma: Emerging Treatments and Novel Trial Designs. *Cancers*, **2021**, 13,	6.6	5
58	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. *Diagnostics*, **2020**, 10,	3.8	4
57	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. *Oncology and Therapy*, **2018**, 6, 105-108	2.7	4
56	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. *Expert Review of Anticancer Therapy*, **2021**, 21, 1333-1353	3.5	4
55	Rare Primary Central Nervous System Tumors in Adults: An Overview. *Frontiers in Oncology*, **2020**, 10, 996	5.3	4
54	Molecular alterations in pancreatic tumors. *World Journal of Gastroenterology*, **2021**, 27, 2710-2726	5.6	4
53	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.. *Frontiers in Oncology*, **2022**, 12, 852950	5.3	4
52	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. *Future Oncology*, **2019**, 15, 2595-2601	3.6	3
51	The burden of oncology promises not kept in glioblastoma. *Future Neurology*, **2018**, 13, 1-4	1.5	3
50	A Randomized Controlled Trial of Tong Len Meditation Practice in Cancer Patients: Evaluation of a Distant Psychological Healing Effect. *Explore: the Journal of Science and Healing*, **2016**, 12, 42-9	1.4	3
49	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. *Childis Nervous System*, **2019**, 35, 2279-2287	1.7	3
48	Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?. *Journal of Clinical Oncology*, **2017**, 35, 2017-2017	2.2	3
47	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. *Journal of Clinical Oncology*, **2018**, 36, 2047-2047	2.2	3
46	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. *Immunotherapy*, **2021**, 13, 419-432	3.8	3
45	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. *Molecular Diagnosis and Therapy*, **2021**, 25, 457-473	4.5	3
44	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. *European Journal of Cancer*, **2021**, 145, 171-178	7.5	3
43	The metastatic process: a kaleidoscope of concepts. *Future Oncology*, **2014**, 10, 697-8	3.6	2
42	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. *Expert Review of Anticancer Therapy*, **2011**, 11, 1713-7	3.5	2

41	Cytologically confirmed splenic metastases in breast cancer. *Future Oncology*, **2012**, 8, 1495-500	3.6	2
40	Gangliogliomas: recent advances in classification and treatment. *Future Neurology*, **2010**, 5, 557-568	1.5	2
39	HER-2 Inhibitors: Clinical Results. *Tumori*, **2002**, 1, S3-S4	1.7	2
38	Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603).. *Journal of Clinical Oncology*, **2012**, 30, 4017-4017	2.2	2
37	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. *Advances in Therapy*, **2021**, 1	4.1	2
36	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. *Immunotherapy* , **2021**,	3.8	2
35	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. *Diagnostics*, **2021**, 11,	3.8	2
34	Glioneuronal tumors: clinicopathological findings and treatment options. *Future Neurology*, **2020**, 15, FNL47	1.5	2
33	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. *European Journal of Cancer*, **2021**, 147, 1-12	7.5	2
32	IDH1 single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. *Pathology Research and Practice*, **2021**, 221, 153445	3.4	2
31	Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. *Cancers*, **2021**, 13,	6.6	2
30	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. *Oncologist*, **2019**, 24, 664-670	5.7	2
29	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. *Drugs*, **2022**, 82, 491	12.1	2
28	The role of gender in glioblastoma: does it matter?. *Future Neurology*, **2016**, 11, 197-199	1.5	1
27	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. *Cancers*, **2022**, 14,	6.6	1
26	Anaplastic gliomas at first recurrence: Outcome analysis.. *Journal of Clinical Oncology*, **2012**, 30, 2061-2061	2.2	1
25	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. *Journal of Clinical Oncology*, **2014**, 32, 7600-7600	2.2	1
24	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.. *Journal of Clinical Oncology*, **2015**, 33, 2047-2047	2.2	1

23	Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.. *Journal of Clinical Oncology*, **2019**, 37, 2028-2028	2.2	1
22	Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.. *Journal of Clinical Oncology*, **2019**, 37, 2037-2037	2.2	1
21	The clinical and prognostic role of ALK in glioblastoma. *Pathology Research and Practice*, **2021**, 221, 153417	3.4	1
20	Immune-checkpoint inhibitors in pituitary malignancies. *Anti-Cancer Drugs*, **2021**, 33,	2.4	1
19	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. *Expert Review of Anticancer Therapy*, **2021**, 21, 1265-1272	3.5	1
18	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. *Tumori*, **2021**, 3008916211017213	1.7	0
17	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. *Clinical Drug Investigation*, **2021**, 41, 757-773	3.2	0
16	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. *Clinical Case Reports (discontinued)*, **2021**, 9, e04604	0.7	0
15	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. *Journal of Molecular Diagnostics*, **2021**, 23, 1185-1194	5.1	0
14	Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. *Neurosurgery*, **2021**, 89, 1042-1051	3.2	0
13	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. *Diagnostics*, **2022**, 12, 1058	3.8	0
12	Concordance between RTOG and EORTC risk factors in low grade gliomas: Who will remain standing in the ring at bell's sound?. *Journal of Clinical Oncology*, **2018**, 36, 2040-2040	2.2	
11	Third-line therapy in glioblastoma: Analysis of a single centre database.. *Journal of Clinical Oncology*, **2018**, 36, e14057-e14057	2.2	
10	Effect of grade on survival in IDH-mutant grade II and grade III gliomas.. *Journal of Clinical Oncology*, **2019**, 37, 2036-2036	2.2	
9	IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas.. *Journal of Clinical Oncology*, **2019**, 37, e14734-e14734	2.2	
8	Association of high volume center with survival for glioblastoma patients: Results from a prospective population-based registry (PERNO).. *Journal of Clinical Oncology*, **2014**, 32, 2048-2048	2.2	
7	Can average-risk medulloblastoma adult patients be treated with radiotherapy and plus chemotherapy?. *Journal of Clinical Oncology*, **2014**, 32, 2022-2022	2.2	
6	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study.. *Journal of Clinical Oncology*, **2016**, 34, 2032-2032	2.2	

5	Medulloblastomas **2011**, 415-433	
4	Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register.. *Journal of Clinical Oncology*, **2012**, 30, 2057-2057	2.2
3	Final results from a large prospective Italian population study on glioblastoma and correlations with MGMT status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO).. *Journal of Clinical Oncology*, **2013**, 31, 2048-2048	2.2
2	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology; PERNO) in newly diagnosed GBM patients (pts): Outcome analysis and correlations with MGMT methylation status in the elderly population.. *Journal of Clinical Oncology*, **2013**, 31, 2021-2021	2.2
1	Adult medulloblastoma **2016**, 582-584	